more

Emergent Biosolutions (EBS)

(Real Time Quote from BATS)

$14.18 USD

+0.37 (2.68%)

Updated Jul 25, 2024 10:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What's in Store for Sangamo (SGMO) This Earnings Season?

by Zacks Equity Research Published on October 29,2018

On Sangamo's (SGMO) Q3 2018 conference call, investor focus will be on the company's progress with its genome editing and gene regulation technology platform.

biotechs

What's in the Cards for Geron (GERN) This Earnings Season?

by Zacks Equity Research Published on October 29,2018

In a major setback to Geron (GERN), J&J terminates collaboration for development of its sole pipeline candidate, imetelstat. Investor focus to remain on path forward for imetelstat.

What's in the Cards for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research Published on October 29,2018

Amarin (AMRN) is scheduled to release third-quarter earnings on Nov 1.

Emergent Biosolutions (EBS) Q3 Earnings Preview: What's Shaping Up?

by Zacks Equity Research Published on October 25,2018

Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EBSPositive Net Change

EBS or ALKS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research Published on October 18,2018

EBS vs. ALKS: Which Stock Is the Better Value Option?

Emergent Completes Acquisition of Narcan Maker Adapt Pharma

by Zacks Equity Research Published on October 16,2018

Emergent (EBS) wraps up the buyout of Adapt Pharma for $735 million. This strategic move will add the latter's popular Narcan nasal spray to its portfolio.

Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up

by Zacks Equity Research Published on October 05,2018

Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.

Emergent (EBS) to Buy Narcan Maker Adapt Pharma for $735M

by Zacks Equity Research Published on August 29,2018

Emergent (EBS) inks a deal to buy Adapt Pharma. This move will add the latter's popular Narcan nasal spray to its portfolio.

Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research Published on August 06,2018

Emergent Biosolutions (EBS) rides high on earnings as well as revenue beat in Q2.

Emergent Biosolutions (EBS) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research Published on August 02,2018

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 11.46% and 5.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

EBSPositive Net Change

EBS vs. NEO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research Published on July 30,2018

EBS vs. NEO: Which Stock Is the Better Value Option?

by Zacks Equity Research Published on July 11,2018

EBS vs. NEO: Which Stock Is the Better Value Option?

What Lies Ahead for Ligand (LGND) This Earnings Season?

by Zacks Equity Research Published on May 02,2018

Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.

Is a Beat in the Cards for Perrigo (PRGO) in Q1 Earnings?

by Zacks Equity Research Published on May 02,2018

Perrigo's (PRGO) product purchases and introductions in the Rx segment might shoot up sales in the near future.

Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store?

by Zacks Equity Research Published on May 02,2018

Investor focus is likely to be on Xyrem's performance, the lead product of Jazz Pharmaceuticals (JAZZ) for excessive daytime sleepiness. Also, the company's pipeline progress might grab attention.

What's in Store for Catalyst (CPRX) This Earnings Season?

by Zacks Equity Research Published on May 02,2018

Catalyst (CPRX) is expected to report first-quarter 2018 results on May 9, after the market closesa and investor's focus will be on pipeline and regulatory updates during the earnings call.